BIM
EPRS

BlackRock Investment Management’s EPIRUS BIOPHARMACEUTICALS INC COM EPRS Stock Holding History

BlackRock Investment Management’s Portfolio EPRS Stock Details EPRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-3,015
Closed -$8K – 4284
2016
Q1 		$8K Hold
3,015
– – ﹤0.01% 3719
2015
Q4 		$9K Buy
3,015
+207
+7% +$933 ﹤0.01% 3746
2015
Q3 		$12K Hold
2,808
– – ﹤0.01% 3636
2015
Q2 		$16K Buy
+2,808
New +$19.2K ﹤0.01% 3546

Other funds holding EPRS

TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 19.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BlackRock Investment Management's EPRS Position: Q2 2016 in Review

BlackRock Investment Management sold out of EPIRUS BIOPHARMACEUTICALS INC COM (EPRS) in Q2 2016, closing a stake of 3,015 shares — an estimated $8K sold.

BlackRock Investment Management first reported a position in EPRS in Q2 2015 and held it in 4 quarters. The position peaked at $16K in Q2 2015. 32 funds tracked by Wall St. Rank hold EPRS as of Q2 2016.

  • BlackRock Investment Management reported no remaining EPIRUS BIOPHARMACEUTICALS INC COM position as of Q2 2016 after selling out during the quarter.
  • BlackRock Investment Management sold 3,015 EPIRUS BIOPHARMACEUTICALS INC COM shares in Q2 2016, an estimated $8K.
  • BlackRock Investment Management first reported a position in EPIRUS BIOPHARMACEUTICALS INC COM in Q2 2015 and held it in 4 quarters.
  • BlackRock Investment Management's EPIRUS BIOPHARMACEUTICALS INC COM position peaked at $16K in Q2 2015.
  • 32 funds tracked by Wall St. Rank held EPIRUS BIOPHARMACEUTICALS INC COM as of Q2 2016.

Based on BlackRock Investment Management's 13F filing for Q2 2016, filed 10 Aug 2016.